Medscape3d
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human epidermal ...
The American Journal of Managed Care5d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
MedPage Today5d
FDA Expands Approval of Ribociclib to Early Breast Cancer
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...
Indiatimes2d
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...
Healthline24d
Side Effects of Kisqali: What You Need to Know
The active ingredient in Kisqali is ribociclib. (An active ingredient is what makes a drug work.) The drug comes as a tablet that you swallow. Keep reading to learn about the common, mild ...
Yahoo Finance5d
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...
WebMD23d
How Kisqali Works for Breast Cancer
How Do I Take Kisqali? Kisqali is taken as a tablet that you swallow. You take Kisqali once a day for 21 days in a row, and then have 7 days where you do not take Kisqali. This means that in every ...
Study finds adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence
The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only ...
STAT4d
FDA awards Novartis expanded approval for breast cancer therapy
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...
AOL16d
Breast cancer drug could help prolong survival for children with brain tumors, study finds
A drug called ribociclib, currently used to treat breast cancer, could slow the progression of certain pediatric high-grade gliomas, an aggressive type of childhood brain cancer, a new study has ...
Rolling Stone29d
Why ‘The Crow’ — and Brandon Lee — Still Haunts Us
It’s a pretty straightforward line of dialogue. But when it was spoken near the end of The Crow, audiences silently shivered. All of us who saw the anticipated comic-book action movie when it ...